Reuters logo
GSK starts big African study of injectable drug to prevent HIV
November 30, 2017 / 8:07 AM / 16 days ago

GSK starts big African study of injectable drug to prevent HIV

(Reuters) - ViiV Healthcare, GlaxoSmithKline Plc’s HIV unit, said on Thursday it started an African study to evaluate long-acting injectable drug for the prevention of HIV infection in sexually active women.

FILE PHOTO: A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville/File Photo

The cabotegravir study seeks to enrol 3,200 women aged 18 to 45 years from sub-Saharan African countries, ViiV Healthcare said in a statement.

The HPTN 084 Phase III study will evaluate injections given every two months, ViiV Healthcare said.

The study is being conducted through a public-private funding by ViiV Healthcare, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Bill & Melinda Gates Foundation, the company said.

Viiv Healthcare in 2016 had started a large study on HIV-uninfected men and transgender women who have sex with men to test an experimental long-acting injection for preventing the virus that causes AIDS.

Reporting by Subrat Patnaik in Bengaluru; Editing by Akshay Lodaya

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below